SCHEMBL6312571

SCHEMBL6312571

CN(C)C1COc2c(C=O)ccc3[nH]cc(c23)C1

nearest known ligand 0.50

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
HTR1D P28221 8/20 0.50
HTR1B P28222 7/20 0.50
HTR1A P08908 2/20 0.39
HTR7 P34969 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6346063 0.88 HTR1D (0.40) HTR1DHTR1BHTR1AHTR7
SCHEMBL6307093 0.85 HTR1D (0.38) HTR1DHTR1BHTR1AHTR7
SCHEMBL6307098 0.85 HTR1D (0.38) HTR1DHTR1BHTR1AHTR7
SCHEMBL6306827 0.82 HTR1D (0.36) HTR1DHTR1BHTR1AHTR7
SCHEMBL6308041 0.81 HTR1A (0.41) HTR1DHTR1BHTR1AHTR7
SCHEMBL8894150 0.80 HTR1D (0.60) HTR1DHTR1BHTR1A
SCHEMBL6304652 0.79 HTR1A (0.43) HTR1DHTR1BHTR1A
SCHEMBL6308276 0.78 HTR1D (0.39) HTR1DHTR1BHTR1AHTR7
SCHEMBL6305587 0.77 HTR7 (0.45) HTR1DHTR1BHTR1AHTR7
SCHEMBL6307417 0.70 HTR7 (0.34) HTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050043387-A1 Tricyclic indole compounds having an affinity against serotonin receptors FUKUI YOSHIKAZU (JP) 2005-02-24 US disclosed
US-6858640-B2 Tricyclic indole compounds having affinity for serotonin receptor SHIONOGI & CO., LTD. (JP) 2005-02-22 US disclosed
US-20030236295-A1 Tricylic indole compounds having affinity for serotonin receptor SHIONOGI & CO., LTD. (JP) 2003-12-25 US disclosed
EP-1325909-A1 TRICYCLIC INDOLE COMPOUNDS HAVING AFFINITY FOR SEROTONIN RECEPTOR SHIONOGI & CO., LTD. (JP) 2003-07-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043387-A1 Tricyclic indole compounds having an affinity against serotonin receptors HTR4, TPH1, HRH4 HTR1D 24/4885HTR1B 10/4885HTR1A 6/4885
US-20030236295-A1 Tricylic indole compounds having affinity for serotonin receptor HTR4, HRH4, TPH1 HTR1D 27/4885HTR1B 26/4885HTR1A 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.